Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP4 | P49662 | 1/20 | 0.47 |
| ▸ | CASP5 | P51878 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.46 |
| ▸ | NCF1 | P14598 | 3/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.42 |
| ▸ | CRHBP | P24387 | 2/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13741399 | 0.86 | ADRB2 (0.48) | CASP1CASP4CASP5HRH4NCF1 | |
| SCHEMBL2349531 | 0.84 | HRH4 (0.48) | CASP1CASP4CASP5HRH4NCF1 | |
| SCHEMBL2001016 | 0.80 | CASP1 (0.44) | CASP1CASP4CASP5HRH4NCF1 | |
| SCHEMBL1045813 | 0.80 | DRD2 (0.50) | DRD2DRD3 | |
| SCHEMBL14538233 | 0.80 | CASP1 (0.53) | CASP1CASP4CASP5HRH4NCF1 | |
| SCHEMBL30376883 | 0.80 | CASP1 (0.53) | CASP1CASP4CASP5HRH4NCF1 | |
| SCHEMBL1764194 | 0.79 | CASP1 (0.43) | CASP1CASP4CASP5HRH4NCF1 | |
| SCHEMBL2346634 | 0.79 | HRH4 (0.57) | CASP1CASP4CASP5HRH4NCF1 | |
| SCHEMBL1763839 | 0.78 | CASP1 (0.42) | CASP1CASP4CASP5HRH4NCF1 | |
| SCHEMBL4390504 | 0.78 | CASP1 (0.42) | CASP1CASP4CASP5HRH4NCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723384-B2 | Keto lactam compounds and use thereof | ABBOTT GMBH & CO. KG. (DE) | 2010-05-25 | — | — | US | disclosed |
| EP-1692129-B1 | KETO LACTAM COMPOUNDS AND USE THEREOF | ABBOTT GMBH & CO KG (DE) | 2008-08-20 | — | — | EP | disclosed |
| US-20070219182-A1 | Keto Lactam Compounds and Use Thereof | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2007-09-20 | — | — | US | disclosed |
| EP-1692129-A1 | KETO LACTAM COMPOUNDS AND USE THEREOF | Abbott GmbH & Co. KG (DE) | 2006-08-23 | — | — | EP | disclosed |
| EP-1484330-B1 | Triazole compouds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | ABBOTT GMBH & CO KG (DE) | 2005-10-26 | — | — | EP | disclosed |
| US-6919342-B2 | Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | ABBOTT GMBH & CO. KG (DE) | 2005-07-19 | — | — | US | disclosed |
| WO-2005056546-A1 | KETO LACTAM COMPOUNDS AND USE THEREOF | ABBOTT GMBH & CO. KG (DE) | 2005-06-23 | — | — | WO | disclosed |
| US-20040259882-A1 | Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2004-12-23 | — | — | US | disclosed |
| WO-2004108706-A1 | TRIAZOLE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2004-12-16 | — | — | WO | disclosed |
| EP-1484330-A1 | Triazole compouds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | Abbott GmbH & Co. KG (DE) | 2004-12-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259882-A1 | Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | DRD3, SLC6A3, DRD2 | CASP1 3071/4885CASP4 4243/4885CASP5 3888/4885 |
| US-20070219182-A1 | Keto Lactam Compounds and Use Thereof | OPRD1, DRD3, OPRK1 | CASP1 1709/4885CASP4 3673/4885CASP5 3731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.